Indeed, disrupting the VDAC1‐HK interaction is a potential strategy for cancer treatment (Cao et al., 2008; Fulda et al., 2010; Galluzzi et al., 2008; Goldin et al., 2008). This evidence concerns the gene HK1 and cancer.